TR199902442T2 - �eker ve �i�manl�k tedavisinde �3 agonistleri olarak tiazol benzens�lfonamidler. - Google Patents
�eker ve �i�manl�k tedavisinde �3 agonistleri olarak tiazol benzens�lfonamidler.Info
- Publication number
- TR199902442T2 TR199902442T2 TR1999/02442T TR9902442T TR199902442T2 TR 199902442 T2 TR199902442 T2 TR 199902442T2 TR 1999/02442 T TR1999/02442 T TR 1999/02442T TR 9902442 T TR9902442 T TR 9902442T TR 199902442 T2 TR199902442 T2 TR 199902442T2
- Authority
- TR
- Turkey
- Prior art keywords
- treatment
- compounds
- agonists
- swelling
- levels
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3676097P | 1997-01-28 | 1997-01-28 | |
| GBGB9705041.3A GB9705041D0 (en) | 1997-03-12 | 1997-03-12 | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR199902442T2 true TR199902442T2 (xx) | 2000-07-21 |
Family
ID=26311166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR1999/02442T TR199902442T2 (xx) | 1997-01-28 | 1998-01-23 | �eker ve �i�manl�k tedavisinde �3 agonistleri olarak tiazol benzens�lfonamidler. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0968209A1 (is) |
| JP (1) | JP2001509166A (is) |
| KR (1) | KR20000070568A (is) |
| CN (1) | CN1251099A (is) |
| AR (1) | AR011092A1 (is) |
| AU (1) | AU728812B2 (is) |
| BG (1) | BG103686A (is) |
| BR (1) | BR9807096A (is) |
| CA (1) | CA2278739A1 (is) |
| EA (1) | EA199900692A1 (is) |
| EE (1) | EE9900328A (is) |
| HR (1) | HRP980044A2 (is) |
| HU (1) | HUP0002053A3 (is) |
| ID (1) | ID22273A (is) |
| IL (1) | IL131130A0 (is) |
| IS (1) | IS5131A (is) |
| NO (1) | NO993646L (is) |
| PE (1) | PE52299A1 (is) |
| PL (1) | PL334833A1 (is) |
| SK (1) | SK100099A3 (is) |
| TR (1) | TR199902442T2 (is) |
| WO (1) | WO1998032753A1 (is) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19824175A1 (de) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
| PT1741446E (pt) | 2000-01-21 | 2008-05-09 | Novartis Pharma Ag | Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos |
| US20030018061A1 (en) * | 2000-01-28 | 2003-01-23 | Kohei Ogawa | Novel remedies with the use of beta 3 agonist |
| TR200401359T4 (tr) | 2000-03-31 | 2004-08-23 | Pfizer Products Inc. | İkame edilmiş piridinlerin hazırlanmasına yönelik işlem |
| ES2398097T3 (es) | 2000-07-13 | 2013-03-13 | Eli Lilly And Company | Agonistas adrenérgicos beta3 |
| US6498170B2 (en) * | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| EP1341759B1 (en) | 2000-11-10 | 2006-06-14 | Eli Lilly And Company | 3-substituted oxindole beta 3 agonists |
| WO2002046186A1 (en) * | 2000-12-08 | 2002-06-13 | Takeda Chemical Industries, Ltd. | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
| AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
| AR035858A1 (es) | 2001-04-23 | 2004-07-21 | Bayer Corp | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 |
| ATE316088T1 (de) * | 2001-06-22 | 2006-02-15 | Merck & Co Inc | Tyrosin-kinase inhibitoren |
| EP1421078B1 (en) | 2001-08-14 | 2006-09-27 | Eli Lilly And Company | Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes |
| AU2002318206A1 (en) | 2001-08-14 | 2003-03-03 | Jolie Anne Bastian | 3-substituted oxindole beta-3 agonists |
| CA2463441A1 (en) * | 2001-10-12 | 2003-05-08 | Bayer Pharmaceuticals Corporation | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
| AU2002353844A1 (en) | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | Beta 3 adrenergic agonists |
| AU2002347982A1 (en) | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | 3-SUBSTITUTED OXINDOLE Beta3 AGONISTS |
| JP2005520805A (ja) | 2002-01-11 | 2005-07-14 | イーライ・リリー・アンド・カンパニー | ２−オキソ−ベンズイミダゾリル置換型エタノールアミン誘導体およびβ３アゴニストとしてのその使用 |
| US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| WO2006132196A1 (ja) * | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | β３作動薬を含有する新規な医薬 |
| PL1931350T5 (pl) | 2005-09-14 | 2021-11-15 | Takeda Pharmaceutical Company Limited | Podanie inhibitorów dipeptydylo-peptydazy |
| BRPI0616463A2 (pt) | 2005-09-29 | 2011-06-21 | Merck & Co Inc | composto, composição farmacêutica, e, uso de um composto |
| CA2624440A1 (en) * | 2005-10-04 | 2007-04-19 | Merck & Co., Inc. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| JP5489333B2 (ja) | 2006-09-22 | 2014-05-14 | メルク・シャープ・アンド・ドーム・コーポレーション | 脂肪酸合成阻害剤を用いた治療の方法 |
| CA2682727C (en) | 2007-04-02 | 2016-03-22 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
| EP2527360B1 (en) | 2007-06-04 | 2015-10-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| PL2531501T3 (pl) | 2010-02-03 | 2014-05-30 | Takeda Pharmaceuticals Co | Inhibitory kinazy 1 regulującej sygnał apoptotyczny |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
| US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| ES2394349B1 (es) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
| US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| SI3004138T1 (sl) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Limited | Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201903832D0 (en) | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0091749A3 (en) * | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) * | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
-
1998
- 1998-01-23 KR KR1019997006814A patent/KR20000070568A/ko not_active Withdrawn
- 1998-01-23 JP JP53214898A patent/JP2001509166A/ja active Pending
- 1998-01-23 AU AU60384/98A patent/AU728812B2/en not_active Ceased
- 1998-01-23 SK SK1000-99A patent/SK100099A3/sk unknown
- 1998-01-23 CA CA002278739A patent/CA2278739A1/en not_active Abandoned
- 1998-01-23 BR BR9807096-7A patent/BR9807096A/pt not_active IP Right Cessation
- 1998-01-23 HU HU0002053A patent/HUP0002053A3/hu unknown
- 1998-01-23 TR TR1999/02442T patent/TR199902442T2/xx unknown
- 1998-01-23 WO PCT/US1998/001317 patent/WO1998032753A1/en not_active Ceased
- 1998-01-23 EA EA199900692A patent/EA199900692A1/ru unknown
- 1998-01-23 EP EP98903677A patent/EP0968209A1/en not_active Withdrawn
- 1998-01-23 EE EEP199900328A patent/EE9900328A/xx unknown
- 1998-01-23 CN CN98803585A patent/CN1251099A/zh active Pending
- 1998-01-23 IL IL13113098A patent/IL131130A0/xx unknown
- 1998-01-23 PL PL98334833A patent/PL334833A1/xx unknown
- 1998-01-23 ID IDW990755A patent/ID22273A/id unknown
- 1998-01-27 AR ARP980100357A patent/AR011092A1/es unknown
- 1998-01-28 HR HR9705041.3A patent/HRP980044A2/hr not_active Application Discontinuation
- 1998-01-28 PE PE1998000064A patent/PE52299A1/es not_active Application Discontinuation
-
1999
- 1999-07-23 IS IS5131A patent/IS5131A/is unknown
- 1999-07-27 NO NO993646A patent/NO993646L/no not_active Application Discontinuation
- 1999-08-24 BG BG103686A patent/BG103686A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EE9900328A (et) | 2000-02-15 |
| BR9807096A (pt) | 2000-04-18 |
| AR011092A1 (es) | 2000-08-02 |
| BG103686A (bg) | 2000-06-30 |
| SK100099A3 (en) | 2000-05-16 |
| AU6038498A (en) | 1998-08-18 |
| IS5131A (is) | 1999-07-23 |
| CN1251099A (zh) | 2000-04-19 |
| ID22273A (id) | 1999-09-23 |
| CA2278739A1 (en) | 1998-07-30 |
| HUP0002053A2 (hu) | 2001-08-28 |
| HRP980044A2 (en) | 1998-10-31 |
| JP2001509166A (ja) | 2001-07-10 |
| EA199900692A1 (ru) | 2000-02-28 |
| IL131130A0 (en) | 2001-01-28 |
| KR20000070568A (ko) | 2000-11-25 |
| AU728812B2 (en) | 2001-01-18 |
| NO993646L (no) | 1999-09-27 |
| WO1998032753A1 (en) | 1998-07-30 |
| EP0968209A1 (en) | 2000-01-05 |
| PE52299A1 (es) | 1999-05-26 |
| NO993646D0 (no) | 1999-07-27 |
| PL334833A1 (en) | 2000-03-27 |
| HUP0002053A3 (en) | 2001-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR199902442T2 (xx) | �eker ve �i�manl�k tedavisinde �3 agonistleri olarak tiazol benzens�lfonamidler. | |
| ES2104259T3 (es) | Fenilsulfonamidas sustituidas como agonistas beta3 selectivos para el tratamiento de la diabetes y la obesidad. | |
| MXPA03000308A (es) | Agonistas beta3 adrenergicos. | |
| HUXTABLE et al. | The effect of a pyrrolizidine alkaloid, monocrotaline, and a pyrrole, dehydroretronecine, on the biochemical functions of the pulmonary endothelium | |
| WO2005097051A3 (en) | Disulfide dyes, composition comprising them and method of dyeing hair | |
| NO964548L (no) | Substituerte sulfonamider som selektive 3 agonister for behandling av diabetes og fedme | |
| ES2048560T3 (es) | Fibra dietetica, su procedimiento y composicion con actividad fisiologica que lo contiene como ingrediente activo. | |
| Ohmiya et al. | Evidence that endo‐1, 4‐β‐glucanases act on cellulose in suspension‐cultured poplar cells | |
| BRPI0408165A (pt) | processos para melhorar a atividade das enzimas de degradação de lignocelulose | |
| ATE260910T1 (de) | 4-heteroaryl-tetrahydrochinoline und ihre verwendung als inhibitoren des cholesterin-ester- transfer-proteins (ctep) | |
| DK0634414T3 (da) | Isolering og struktur af spongistatin 5,7,8 og 9 og deres anvendelse som antitumormidler | |
| DE60023660D1 (de) | Antizymmodulatoren sowie deren verwendung | |
| Mountfort | The rumen anaerobic fungi | |
| KR870008025A (ko) | 정상 인체 결장 세포로 부터 인체조직 푸라스미노겐 활성화인자 | |
| DK1218494T3 (da) | Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler | |
| BRPI0418462A (pt) | derivados de tetrahidroisoquinolina e terahidrobenzazepina como inibidores igf-1r | |
| Hsieh et al. | Regulation of basal and luminal cell-specific cytokeratin expression in rat accessory sex organs. Evidence for a new class of androgen-repressed genes and insight into their pairwise control. | |
| MASUDA et al. | Further studies on the role of cell-wall-degrading enzymes in cell-wall loosening in oat coleoptiles | |
| DE69116192D1 (de) | Für die Polysaccharidhydrolyse aus einem lignozellulosehaltigen Substrat geeignete Enzymzusammensetzung, ihre Herstellung und Verwendung | |
| Macris et al. | Production and cross-synergistic action of cellulolytic enzymes from certain fungal mutants grown on cotton and straw | |
| Kosugi et al. | Degradation of cellulosome-produced cello-oligosaccharides by an extracellular non-cellulosomal β-glucan glucohydrolase, BglA, from Clostridium cellulovorans | |
| ES2111741T3 (es) | Microorganismo cepa w, composicion enzimatica obtenible a partir de este, utilizacion del microorganismo y procedimiento para la hidrolisis particularmente de queratina. | |
| Borgers et al. | The development of alkaline phosphatase in trichinous muscle | |
| Xu et al. | Purification and characterization of an endo-1, 4-β-D glucanase from the cellulolytic system of the wood-boring marine mollusk Lyrodus pedicellatus (Bivalvia: Teredinidae) | |
| BR0011905A (pt) | Processo para gerar células e tecidos imunocompatìveis usando-se técnicas de transferência nuclear |